- Molecular NameKanamycin
- SynonymAminodeoxykanamycin; KAN; Kanamycin Base; Kanamycin Sulfate; Nebramycin Factor 5
- Weight526.54
- Drugbank_IDDB01172
- ACS_NO59-01-8
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-7.98
- pka7.2
- LogD (pH=7, predicted)-10.39
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)0.28
- LogSw (predicted, AB/LogsW2.0)890.55
- Sw (mg/ml) (predicted, ACD/Labs)1000.0
- No.of HBond Donors14
- No.of HBond Acceptors16
- No.of Rotatable Bonds7
- TPSA285.69
- StatusFDA approved
- AdministrationOral, intravenous, intramuscular
- PharmacologyAn aminoglycoside antibiotic, available in both oral and intravenous forms, and used to treat a wide variety of infections. Kanamycin is isolated from Streptomyces kanamyceticus
- Absorption_value1.0
- Absorption (description)Kanamycin is poorly absorbed after oral administration, but rapidly and completely absorbed after IM injection.
- Caco_2N/A
- Bioavailability1.0
- Protein binding0.0
- Volume of distribution (VD)0.3 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmThe transformation of kanamicin is neglible.
- Half life2~4 h; increased to 4 to 5 days in renal failure.
- ExcretionUp to 95% of a dose is excreted unchanged in the urine in 24 h, most being excreted within the first 6 h. A small amount is excreted in the bile.
- Urinary ExcretionN/A
- Clerance1.4 ml/min/kg
- ToxicityToxic effects may be produced at serum concentrations of 30 mg/L or more, or during chronic treatment if the trough serum concentration exceeds 10 mg/L.
- LD50 (rat)N/A
- LD50 (mouse)N/A